Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
OBJECTIVE
A 16 year review of persistent gestational trophoblastic tumour when the antecedent pregnancy was a partial hydatidiform mole.


METHODS
Cases of persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy were reviewed for the period 1976 to 1992. DNA ploidy was analysed by flow cytometry.


METHODS
A University Hospital which is a reference centre for gestational trophoblastic tumour.


METHODS
The case notes of 207 women with persistent gestational trophoblastic tumour were reviewed.


METHODS
A rise (or failure to fall) of beta hCG titre, or sign of metastasis.


RESULTS
Six (2.9%) women had partial hydatidiform mole as the antecedent pregnancy and all were initially judged to be low risk. However, two developed pulmonary metastasis; one woman developed persistent gestational trophoblastic tumour shortly after a hysterotomy, and none developed choriocarcinoma. The geometric mean of serum beta hCG concentrations at the initiation of chemotherapy was 868 mIU/ml (95% CI 114-1524). Of the six women, one achieved remission after total abdominal hysterectomy, and five after chemotherapy. The mean interval from starting treatment to remission was 68 days (95% CI 27.9-108.0). The initial beta hCG titre and interval were not statistically different from those found in cases of persistent gestational trophoblastic tumour when the antecedent pregnancy was not partial hydatidiform mole. Of the six, the DNA content was triploid in three and diploid in two. One of the two diploid cases required multiple courses of chemotherapy to achieve remission.


CONCLUSIONS
Partial hydatidiform mole can have malignant sequelae and can develop very soon after treatment. Its DNA content can be either diploid or triploid, the lungs being the most common site of metastasis. After evacuation of partial hydatidiform mole, immediate chest X-ray and regular follow up of the serum beta hCG level is necessary.
Chen
R J
RJ
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei.
Huang
S C
SC
Chow
S N
SN
Hsieh
C Y
CY
Hsu
H C
HC
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood*; D004247:DNA / Q000235:genetics; D004107:Dilatation and Curettage; D004171:Diploidy; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood / Q000150:complications*; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D011247:Pregnancy; D012189:Retrospective Studies; D014328:Trophoblastic Neoplasms / Q000097:blood / Q000209:etiology*; D014594:Uterine Neoplasms / Q000097:blood / Q000150:complications*
D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin; D004247:DNA